FI964712A0 - Kinoliinijohdannaisia takykiniini NK3-reseptoriantagonisteina - Google Patents
Kinoliinijohdannaisia takykiniini NK3-reseptoriantagonisteinaInfo
- Publication number
- FI964712A0 FI964712A0 FI964712A FI964712A FI964712A0 FI 964712 A0 FI964712 A0 FI 964712A0 FI 964712 A FI964712 A FI 964712A FI 964712 A FI964712 A FI 964712A FI 964712 A0 FI964712 A0 FI 964712A0
- Authority
- FI
- Finland
- Prior art keywords
- tachykinin
- receptor antagonists
- quinoline derivatives
- quinoline
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
- C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Ceramic Engineering (AREA)
- Pain & Pain Management (AREA)
- Manufacturing & Machinery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Structural Engineering (AREA)
- Immunology (AREA)
- Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Materials Engineering (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Anesthesiology (AREA)
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT94MI001099A ITMI941099A1 (it) | 1994-05-27 | 1994-05-27 | Derivati chinolinici |
ITMI941099 | 1994-05-27 | ||
IT95MI000494 IT1293558B1 (it) | 1995-03-14 | 1995-03-14 | Derivati chinolinici |
ITMI950494 | 1995-03-14 | ||
PCT/EP1995/002000 WO1995032948A1 (en) | 1994-05-27 | 1995-05-23 | Quinoline derivatives as tachykinin nk3 receptor antagonists |
EP9502000 | 1995-05-23 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI964712A0 true FI964712A0 (fi) | 1996-11-26 |
FI964712A FI964712A (fi) | 1997-01-23 |
FI115052B FI115052B (fi) | 2005-02-28 |
Family
ID=26331143
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI964712A FI115052B (fi) | 1994-05-27 | 1996-11-26 | Kinoliinijohdannaisia takykiniini-NK3-reseptoriantagonisteina |
FI990268A FI119721B (fi) | 1994-05-27 | 1999-02-10 | Ei-peptidi-NK-antagonistin käyttö ihosairauksien ja kutinan hoitoon tarkoitettujen lääkkeiden valmistukseen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI990268A FI119721B (fi) | 1994-05-27 | 1999-02-10 | Ei-peptidi-NK-antagonistin käyttö ihosairauksien ja kutinan hoitoon tarkoitettujen lääkkeiden valmistukseen |
Country Status (35)
Country | Link |
---|---|
US (5) | US5811553A (fi) |
EP (2) | EP0804419B1 (fi) |
JP (5) | JP3664492B2 (fi) |
KR (1) | KR100316571B1 (fi) |
CN (3) | CN1092642C (fi) |
AP (1) | AP578A (fi) |
AR (1) | AR037069A2 (fi) |
AT (2) | ATE273959T1 (fi) |
AU (1) | AU699319B2 (fi) |
BG (2) | BG64004B1 (fi) |
BR (1) | BR9507788A (fi) |
CA (1) | CA2191352C (fi) |
CZ (1) | CZ291476B6 (fi) |
DE (2) | DE69531458T2 (fi) |
DK (1) | DK0804419T3 (fi) |
DZ (1) | DZ1889A1 (fi) |
ES (2) | ES2204952T3 (fi) |
FI (2) | FI115052B (fi) |
HK (2) | HK1003884A1 (fi) |
HU (1) | HU226535B1 (fi) |
IL (1) | IL113844A (fi) |
MA (1) | MA23560A1 (fi) |
MX (1) | MX9605903A (fi) |
MY (1) | MY129596A (fi) |
NO (2) | NO307783B1 (fi) |
NZ (1) | NZ287442A (fi) |
OA (1) | OA10592A (fi) |
PL (2) | PL186075B1 (fi) |
PT (2) | PT940391E (fi) |
RO (1) | RO114445B1 (fi) |
SA (1) | SA95160290B1 (fi) |
SK (2) | SK282721B6 (fi) |
TW (2) | TW533199B (fi) |
UA (1) | UA51623C2 (fi) |
WO (1) | WO1995032948A1 (fi) |
Families Citing this family (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0804419B1 (en) * | 1994-05-27 | 2003-08-06 | SmithKline Beecham Farmaceutici S.p.A. | Quinoline derivatives as tachykinin nk 3 receptor antagonists |
EA002124B1 (ru) * | 1995-11-24 | 2001-12-24 | Смитклайн Бичам С.П.А. | Производные хинолина |
GB9524137D0 (en) * | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
GB9524104D0 (en) * | 1995-11-24 | 1996-01-24 | Smithkline Beecham Spa | Novel compounds |
AR004735A1 (es) * | 1995-11-24 | 1999-03-10 | Smithkline Beecham Spa | Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento. |
AU757836B2 (en) * | 1995-11-24 | 2003-03-06 | Smithkline Beecham Spa | Quinoline derivatives |
CA2284035A1 (en) * | 1997-03-14 | 1998-09-24 | Smithkline Beecham Corporation | Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
US6077850A (en) * | 1997-04-21 | 2000-06-20 | G.D. Searle & Co. | Substituted benzopyran analogs for the treatment of inflammation |
US20010012846A1 (en) * | 1997-05-23 | 2001-08-09 | Glardina Giuseppe Arnaldo Maria | Quinoline-4-carboxamide derivatives as NK-2 and NK-3 receptor antagonists |
SK159299A3 (en) * | 1997-05-23 | 2000-06-12 | Smithkline Beecham Spa | Quinoline-4-carboxamide derivatives as nk-2 and nk-3 receptor antagonists |
EP1652840A3 (en) * | 1997-09-17 | 2006-05-17 | Smithkline Beecham Corporation | (-)-(S)-N-(.alpha.-ethylbenzyl)-3-hydroxy-2-phenylquinoline-4-carboxamide |
AP1201A (en) * | 1997-09-17 | 2003-09-01 | Smithkline Beecham Corp | Method for the synthesis of quinoline derivatives. |
US6083944A (en) * | 1997-10-07 | 2000-07-04 | Cephalon, Inc. | Quinoline-containing α-ketoamide cysteine and serine protease inhibitors |
GB9825554D0 (en) | 1998-11-20 | 1999-01-13 | Smithkline Beecham Spa | Novel Compounds |
US6780875B2 (en) * | 1998-11-20 | 2004-08-24 | Smithkline Beecham S.P.A. | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists |
AR021355A1 (es) * | 1998-11-20 | 2002-07-17 | Smithkline Beecham Spa | Derivados de quinolina. procedimiento para su preparacion, composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de unmedicamento |
ATE290862T1 (de) * | 1999-01-25 | 2005-04-15 | Smithkline Beecham Corp | Anti-androgene und verfahren zur behandlung von krankheiten |
US7037922B1 (en) | 2000-03-10 | 2006-05-02 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: NK3 receptor ligands |
AU4038000A (en) | 1999-03-29 | 2000-10-16 | Neurogen Corporation | 4-substituted quinoline derivatives as gaba receptor ligands |
WO2000064877A1 (en) | 1999-04-26 | 2000-11-02 | Neurogen Corporation | 2-aminoquinolinecarboxamides: neurokinin receptor ligands |
US6521618B2 (en) | 2000-03-28 | 2003-02-18 | Wyeth | 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors |
WO2002013825A1 (en) * | 2000-08-11 | 2002-02-21 | Smithkline Beecham P.L.C. | Novel pharmaceutical use of quinnoline derivatives |
GB0028964D0 (en) * | 2000-11-28 | 2001-01-10 | Smithkline Beecham Spa | Novel compounds |
US6540733B2 (en) * | 2000-12-29 | 2003-04-01 | Corazon Technologies, Inc. | Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
ES2254688T3 (es) * | 2001-04-11 | 2006-06-16 | Glaxosmithkline S.P.A. | Derivados de quinolina-4-carboxamida como antagonistas de los receptores nk-3 y nk-2. |
US20040152727A1 (en) * | 2001-05-18 | 2004-08-05 | Hay Douglas William Pierre | Novel use |
WO2004002484A1 (ja) * | 2002-06-26 | 2004-01-08 | Kyowa Hakko Kogyo Co., Ltd. | ホスホジエステラーゼ阻害剤 |
GB0228288D0 (en) * | 2002-12-04 | 2003-01-08 | Smithkline Beecham Corp | Chemical compounds |
GB0228287D0 (en) * | 2002-12-04 | 2003-01-08 | Smithkline Beecham Corp | Chemical compounds |
GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
SE0302139D0 (sv) * | 2003-07-28 | 2003-07-28 | Astrazeneca Ab | Novel compounds |
ATE440866T1 (de) | 2003-12-22 | 2009-09-15 | Glaxo Group Ltd | Nogo-a-neutralisierende immunglobuline zur behandlung neurologischer krankheiten |
JP2007520543A (ja) | 2004-02-04 | 2007-07-26 | ファイザー・プロダクツ・インク | 置換キノリン化合物 |
US20070244152A1 (en) * | 2004-03-25 | 2007-10-18 | Lowy Martin T | Use of an Nk3 Antagonist for the Treatment of Bipolar Disorders |
EP1729734B1 (en) * | 2004-03-30 | 2008-02-27 | Smithkline Beecham Corporation | Spray dried pharmaceutical compositions |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
NZ587551A (en) * | 2004-06-24 | 2012-01-12 | Vertex Pharma | 5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol |
GB0417560D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Therapeutic compounds |
GB0417559D0 (en) * | 2004-08-06 | 2004-09-08 | Merck Sharp & Dohme | Therapeutic compounds |
GB0425076D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0425077D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0425075D0 (en) * | 2004-11-12 | 2004-12-15 | Smithkline Beecham Corp | Novel compounds |
GB0428233D0 (en) * | 2004-12-23 | 2005-01-26 | Glaxo Group Ltd | Compounds |
JP2008542367A (ja) * | 2005-06-03 | 2008-11-27 | アストラゼネカ・アクチエボラーグ | Nk−3アンタゴニストとしてのキノリン誘導体 |
JP2008546767A (ja) * | 2005-06-23 | 2008-12-25 | アストラゼネカ・アクチエボラーグ | Nk3受容体のモジュレーターとしてのキノリン3−スルホン酸エステル |
GB0515580D0 (en) | 2005-07-29 | 2005-09-07 | Merck Sharp & Dohme | Therapeutic compounds |
WO2007016609A2 (en) * | 2005-08-02 | 2007-02-08 | Smithkline Beecham Corporation | Method for the synthesis of quinoliνe derivatives |
WO2007018469A1 (en) * | 2005-08-11 | 2007-02-15 | Astrazeneca Ab | Oxopyridyl quinoline amides as nk3 receptor modulators |
EP1915362A1 (en) * | 2005-08-11 | 2008-04-30 | AstraZeneca AB | Amide alkyl pyridiyl quinolines as nk3 receptor modulators |
AR058051A1 (es) * | 2005-09-21 | 2008-01-23 | Astrazeneca Ab | Quinolinas de alquilnitrilo.proceso de obtencion y composiciones farmaceuticas. |
EP1940795A1 (en) * | 2005-09-21 | 2008-07-09 | AstraZeneca AB | N-oxo-heterocycle and n-oxo-alkyl quinoline-4-carboxamides as nk-3 receptor ligands |
AR057130A1 (es) | 2005-09-21 | 2007-11-14 | Astrazeneca Ab | Quinolinas de alquilsulfoxido y una composicion farmaceutica |
TW201018662A (en) * | 2005-12-12 | 2010-05-16 | Astrazeneca Ab | Alkylsulphonamide quinolines |
GB0525662D0 (en) | 2005-12-16 | 2006-01-25 | Glaxo Group Ltd | Immunoglobulins |
US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
PL3219705T3 (pl) * | 2005-12-28 | 2020-08-10 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne amorficznych postaci n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4-dihydro-4-oksochinolino-3-karboksyamidu |
CN101410392A (zh) * | 2006-01-27 | 2009-04-15 | 阿斯利康(瑞典)有限公司 | 酰胺取代的喹啉类化合物 |
GB0603087D0 (en) * | 2006-02-15 | 2006-03-29 | Glaxo Group Ltd | Novel use |
AR065806A1 (es) | 2007-03-22 | 2009-07-01 | Astrazeneca Ab | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. |
WO2008131779A1 (en) | 2007-04-26 | 2008-11-06 | H. Lundbeck A/S | Isoquinolinone derivatives as nk3 antagonists |
US8173639B2 (en) | 2007-04-26 | 2012-05-08 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
BRPI0816239A2 (pt) * | 2007-08-22 | 2015-02-24 | Allergan Inc | Derivados terapêuticos de quinolina e naftaleno |
WO2009049791A2 (en) * | 2007-10-15 | 2009-04-23 | F. Hoffmann-La Roche Ag | Radiolabeled nk3 receptor antagonist |
US8106073B2 (en) | 2007-11-30 | 2012-01-31 | Astrazeneca Ab | Quinoline derivatives 057 |
ES2401059T3 (es) * | 2008-06-23 | 2013-04-16 | H. Lundbeck A/S | Derivados de isoquinolinona como antagonistas de NK3 |
US8242134B2 (en) | 2008-09-15 | 2012-08-14 | H. Lundbeck A/S | Isoquinolinone derivatives as NK3 antagonists |
CN102256948A (zh) | 2008-10-20 | 2011-11-23 | H.隆德贝克有限公司 | 用作nk3拮抗剂的异喹啉酮衍生物 |
KR101852173B1 (ko) | 2009-03-20 | 2018-04-27 | 버텍스 파마슈티칼스 인코포레이티드 | 낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법 |
TW201143768A (en) | 2009-12-15 | 2011-12-16 | Lundbeck & Co As H | Pyridone derivatives as NK3 antagonists |
TW201144311A (en) | 2010-03-12 | 2011-12-16 | Lundbeck & Co As H | Azaisoquionolinone derivatives as NK3 antagonists |
US8487102B2 (en) * | 2010-04-20 | 2013-07-16 | Hoffmann-La Roche Inc. | Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
CN109966264A (zh) | 2012-02-27 | 2019-07-05 | 沃泰克斯药物股份有限公司 | 药物组合物及其施用 |
CN102702099A (zh) * | 2012-06-21 | 2012-10-03 | 江苏恩华药业股份有限公司 | (s)-3-羟基-2-苯基-n-(1-苯基丙基)喹啉-4-甲酰胺的制备方法 |
EP2986293A1 (en) | 2013-04-19 | 2016-02-24 | Astrazeneca AB | A nk3 receptor antagonist compound (nk3ra) for use in a method for the treatment of polycystic ovary syndrome (pcos) |
EP3915560A1 (en) | 2014-06-25 | 2021-12-01 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
WO2016004035A1 (en) * | 2014-07-01 | 2016-01-07 | Icahn School Of Medicine At Mount Sinai | 2-aryl-4-quinolinecarboxamide derivatives for treating thyroid diseases |
CA2960324A1 (en) | 2014-09-09 | 2016-03-17 | Bayer Pharma Aktiengesellschaft | Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents |
US9701639B2 (en) | 2014-10-07 | 2017-07-11 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
CA2979926A1 (en) | 2015-03-18 | 2016-09-22 | Bayer Pharma Aktiengesellschaft | Substituted n-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof |
AU2016264034B2 (en) * | 2015-05-18 | 2020-03-05 | KaNDy Therapeutics Limited | Dual NK-1/NK-3 receptor antagonists for the treatment of sex-hormone-dependent diseases |
WO2017072629A1 (en) | 2015-10-29 | 2017-05-04 | Cadila Healthcare Limited | Pharmaceutical combination of nk3 receptor antagonist and biguanides |
WO2017153231A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung |
WO2017153234A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung |
WO2017153235A1 (de) | 2016-03-09 | 2017-09-14 | Bayer Pharma Aktiengesellschaft | Substituierte n-cyclo-3-aryl-1-naphthamide und ihre verwendung |
CN105884626B (zh) * | 2016-05-04 | 2017-10-20 | 龙曦宁(上海)医药科技有限公司 | 一种2‑氨基茚满衍生物的合成方法及其产品 |
TWI770157B (zh) * | 2017-04-10 | 2022-07-11 | 德商拜耳廠股份有限公司 | 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途 |
CA3059273A1 (en) * | 2017-04-10 | 2018-10-18 | Bayer Aktiengesellschaft | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof |
US11458129B2 (en) | 2017-11-02 | 2022-10-04 | California Institute Of Technology | Neurokinin antagonists and uses thereof |
CN113194948A (zh) * | 2018-11-15 | 2021-07-30 | 国立大学法人九州大学 | Il-31介导性疾病的预防或治疗剂及医药组合物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1560489A (en) * | 1976-05-21 | 1980-02-06 | Fisons Ltd | Pharmaceutical compositions |
FR2538388B1 (fr) | 1982-12-24 | 1985-06-21 | Pharmuka Lab | Nouveaux derives de naphtalene- ou azanaphtalenecarboxamide, leurs procedes de preparation et leur utilisation comme medicaments |
DE3905339A1 (de) * | 1989-02-22 | 1990-09-06 | Basf Ag | Chinolin-4-carbonsaeurederivate und deren verwendung |
US4992448A (en) * | 1989-10-24 | 1991-02-12 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
US5037835A (en) * | 1989-10-24 | 1991-08-06 | Hoechst-Roussel Pharmaceuticals Inc. | Benzocycloalkylaminopyridinamines and related compounds as topical antiinflammatory agents for the treatment of skin disorders |
EP0449565B1 (en) * | 1990-03-26 | 1997-05-14 | Matsushita Electric Industrial Co., Ltd. | Photosensitive material for electrophotography |
NO179904C (no) * | 1992-09-04 | 1997-01-08 | Takeda Chemical Industries Ltd | Kondenserte heterocykliske forbindelser og deres anvendelse |
US5434158A (en) * | 1994-04-26 | 1995-07-18 | Merck & Co., Inc. | Spiro-substituted azacycles as neurokinin-3 antagonists |
EP0804419B1 (en) | 1994-05-27 | 2003-08-06 | SmithKline Beecham Farmaceutici S.p.A. | Quinoline derivatives as tachykinin nk 3 receptor antagonists |
US5607936A (en) * | 1994-09-30 | 1997-03-04 | Merck & Co., Inc. | Substituted aryl piperazines as neurokinin antagonists |
-
1995
- 1995-05-23 EP EP95920894A patent/EP0804419B1/en not_active Expired - Lifetime
- 1995-05-23 CN CN95194338A patent/CN1092642C/zh not_active Expired - Fee Related
- 1995-05-23 PT PT98204483T patent/PT940391E/pt unknown
- 1995-05-23 WO PCT/EP1995/002000 patent/WO1995032948A1/en active IP Right Grant
- 1995-05-23 KR KR1019960706701A patent/KR100316571B1/ko not_active IP Right Cessation
- 1995-05-23 DK DK95920894T patent/DK0804419T3/da active
- 1995-05-23 SK SK1514-96A patent/SK282721B6/sk not_active IP Right Cessation
- 1995-05-23 AU AU26164/95A patent/AU699319B2/en not_active Ceased
- 1995-05-23 JP JP50028796A patent/JP3664492B2/ja not_active Expired - Fee Related
- 1995-05-23 PT PT95920894T patent/PT804419E/pt unknown
- 1995-05-23 UA UA96124918A patent/UA51623C2/uk unknown
- 1995-05-23 BR BR9507788A patent/BR9507788A/pt not_active IP Right Cessation
- 1995-05-23 PL PL95317381A patent/PL186075B1/pl not_active IP Right Cessation
- 1995-05-23 NZ NZ287442A patent/NZ287442A/en not_active IP Right Cessation
- 1995-05-23 AT AT98204483T patent/ATE273959T1/de not_active IP Right Cessation
- 1995-05-23 HU HU9603262A patent/HU226535B1/hu not_active IP Right Cessation
- 1995-05-23 ES ES95920894T patent/ES2204952T3/es not_active Expired - Lifetime
- 1995-05-23 DE DE69531458T patent/DE69531458T2/de not_active Expired - Lifetime
- 1995-05-23 DE DE69533408T patent/DE69533408T2/de not_active Expired - Lifetime
- 1995-05-23 CA CA002191352A patent/CA2191352C/en not_active Expired - Fee Related
- 1995-05-23 CZ CZ19963470A patent/CZ291476B6/cs not_active IP Right Cessation
- 1995-05-23 SK SK47-99A patent/SK282722B6/sk not_active IP Right Cessation
- 1995-05-23 ES ES98204483T patent/ES2227769T3/es not_active Expired - Lifetime
- 1995-05-23 EP EP98204483A patent/EP0940391B1/en not_active Expired - Lifetime
- 1995-05-23 RO RO96-02234A patent/RO114445B1/ro unknown
- 1995-05-23 AT AT95920894T patent/ATE246677T1/de not_active IP Right Cessation
- 1995-05-23 PL PL95341889A patent/PL186665B1/pl not_active IP Right Cessation
- 1995-05-24 AP APAP/P/1995/000745A patent/AP578A/en active
- 1995-05-24 DZ DZ950061A patent/DZ1889A1/fr active
- 1995-05-25 IL IL11384495A patent/IL113844A/xx not_active IP Right Cessation
- 1995-05-25 MY MYPI95001381A patent/MY129596A/en unknown
- 1995-05-25 MA MA23898A patent/MA23560A1/fr unknown
- 1995-05-25 US US08/450,438 patent/US5811553A/en not_active Expired - Lifetime
- 1995-05-25 US US08/450,437 patent/US6608083B1/en not_active Expired - Fee Related
- 1995-05-26 TW TW088121625A patent/TW533199B/zh not_active IP Right Cessation
- 1995-05-26 TW TW084105319A patent/TW427977B/zh not_active IP Right Cessation
- 1995-10-03 SA SA95160290A patent/SA95160290B1/ar unknown
-
1996
- 1996-11-25 BG BG101008A patent/BG64004B1/bg unknown
- 1996-11-26 MX MX9605903A patent/MX9605903A/es not_active IP Right Cessation
- 1996-11-26 FI FI964712A patent/FI115052B/fi active IP Right Grant
- 1996-11-26 NO NO965036A patent/NO307783B1/no unknown
- 1996-11-27 OA OA60928A patent/OA10592A/en unknown
-
1998
- 1998-04-09 HK HK98103021A patent/HK1003884A1/xx not_active IP Right Cessation
-
1999
- 1999-01-15 CN CN99100978A patent/CN1276211A/zh active Pending
- 1999-02-10 FI FI990268A patent/FI119721B/fi active IP Right Grant
- 1999-02-16 BG BG103181A patent/BG103181A/bg unknown
- 1999-04-16 NO NO991813A patent/NO326714B1/no unknown
- 1999-06-18 JP JP11172597A patent/JP2000026314A/ja active Pending
-
2000
- 2000-03-06 HK HK00101401A patent/HK1024469A1/xx not_active IP Right Cessation
- 2000-06-22 AR ARP000103117A patent/AR037069A2/es unknown
-
2001
- 2001-05-29 US US09/867,133 patent/US20030236281A1/en not_active Abandoned
- 2001-10-24 JP JP2001326622A patent/JP2002179594A/ja active Pending
-
2002
- 2002-03-18 CN CN02107941A patent/CN1428145A/zh active Pending
-
2004
- 2004-09-30 JP JP2004287629A patent/JP2005068155A/ja active Pending
- 2004-11-29 US US10/999,180 patent/US20050096316A1/en not_active Abandoned
-
2006
- 2006-03-21 US US11/385,461 patent/US7482458B2/en not_active Expired - Fee Related
- 2006-12-28 JP JP2006355694A patent/JP2007126475A/ja not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI964712A0 (fi) | Kinoliinijohdannaisia takykiniini NK3-reseptoriantagonisteina | |
NO951613D0 (no) | Ikke-peptidyl tachykinin reseptorantagonister | |
ID19623A (id) | Antagonis reseptor vitronektin | |
NO972526D0 (no) | Tachykininantagonister | |
DK0922034T3 (da) | Tetrahydroquinolinderivater som EAA-antagonister | |
DK0854867T3 (da) | Tetrahydroquinoliner som NMDA-antagonister | |
DK0906294T3 (da) | Benzoxazinon-dopamin D4-receptor-antagonister | |
ID24468A (id) | 2-asilaminopropanamina sebagai antagonis reseptor tachykinin | |
NO985970D0 (no) | Indolinderivater anvendelige som 5_HT-2C-reseptor-antagonister | |
DK1086093T3 (da) | Tetrahydroquinolinderivater som glycinantagonister | |
FI951798A0 (fi) | Bentsofuraanijohdannaiset 5-HT1-kaltaisina reseptoriantagonisteina | |
NO985972D0 (no) | Indolinderivater anvendelige som 5-HT-2C reseptorantagonister | |
DK0815105T3 (da) | Heterocyklisk substituerede piperazinonderivater som tachykininreceptor-antagonister | |
ID24309A (id) | 2-asilaminopropanamina sebagai antagonis reseptor tachykinin | |
NO20002575D0 (no) | Substituerte oksimer som neurokininantagonister | |
DK0940391T3 (da) | Quinolinderivater som tachykinin-NK3-receptor-antagonister | |
SI0940391T1 (en) | Quinoline derivatives as tachykinin NK3 receptor antagonists | |
FI970143A (fi) | Kinoliinijohdannaiset leukotrieeniantagonisteina | |
DK0964867T3 (da) | Tachykininantagonister |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 115052 Country of ref document: FI |